MEDDEV271rev4附中文.docx
《MEDDEV271rev4附中文.docx》由会员分享,可在线阅读,更多相关《MEDDEV271rev4附中文.docx(5页珍藏版)》请在冰豆网上搜索。
MEDDEV271rev4附中文
MEDDEV2.7.1rev42016附中文
__.71revision4June2022年GuidelinesonMedicalDevicesClinicalEvaluation:
AGuideforManufacturersAndNotifiedBodiesUnderDirectives9342EECand__EEC
__N__ION
DGInternalMarket,Industry,EntrepreneurshipandSMEs
Consumer,EnvironmentalandHealthTechnologies
HealthtechnologyandCosmetics
备注:
中文翻译中的临床调查=临床研究,评估=评价、设备=器械、数据=资料
Note
ThepresentGuidelinesarepartofasetofGuidelinesrelatingtoquestionsofapplicationofEC-DirectivesonmedicalDevices.Theyarelegallynotbinding.TheGuidelineshavebeencarefullydraftedthroughaprocessofintensiveconsultationofthevariousinterestedparties(competentauthorities,Commissionservices,industries,otherinterestedparties)duringwhichintermediatedraftswherecirculatedandcommentsweretakenupinthedocument.Therefore,thisdocumentreflectspositionstakenbyrepresentativesofinterestpartiesinthemedicaldevicessector.TheseguidelinesincorporatechangesintroducedbyDirective2022年/47/ECamendingCouncilDirective90/385/EECandCouncilDirective93/42/EEC.
本指南为一系列与CE―医疗器械指令应用问题相关的指南中的一部分。
并不具有法律约束力。
该指南在经过与各个利益方(主管当局、服务委员会、行业委员会、其他利益相关团体)进行深入协商之后谨慎拟定而成,期间对中期草案进行了传阅,而且部分意见还为本文件所采纳。
因此,本文件反映出了来自医疗器械行业的利益团体代表所持的立场。
本指南包含了指令2022年/47/EC对90/385/EEC和93/42/EEC修正中的变更
(没规定实施时间)
__.71revision4June2022年GuidelinesonMedicalDevicesClinicalEvaluation:
AGuideforManufacturersAndNotifiedBodiesUnderDirectives9342EECand__EEC
______VES
__L__GATION
__L__ION:
AGUIDEFOR__TURERSAND__DBODIES
UNDER__VES93/42/EECand90/385/EEC
Index
1.Introduction(4)
2.Scope(4)
3.References(4)
4.Definitions(5)
5.Abbreviations(8)
6.Generalprinciplesofclinicalevaluation(9)
6.1.Whatisclinicalevaluation?
(9)
6.2.Whenisclinicalevaluationundertakenandwhyisitimportant?
(10)
6.2.1.Clinicalevaluationundertakenforthedevelopmentofamedicaldevice(10)
6.2.2.ClinicalevaluationforinitialCE-marking(11)
6.2.3.Updatingtheclinicalevaluation(11)
6.3.Howisaclinicalevaluationperformed?
(13)
6.4.Whoshouldperformtheclinicalevaluation?
(14)
7.Definitionofthescopeoftheclinicalevaluation(Stage0)(15)
8.Identificationofpertinentdata(Stage1)(17)
8.1.Datageneratedandheldbythemanufacturer(17)
8.2.Dataretrievedfromliterature(18)
9.Appraisalofpertinentdata(Stage2)(19)
9.1.Generalconsiderations(19)
9.2.Theappraisalplan(20)
9.3.Conductoftheappraisal(20)
9.3.1.Howtoevaluatemethodologicalqualityandscientificvalidity(20)
9.3.2.Howtodeterminetherelevanceofadatasetfortheclinicalevaluation(24)
9.3.3.Howtoweightthecontributionofeachdataset(26)
10.Analysisoftheclinicaldata(Stage3)(27)
10.1.Generalconsiderations(27)
10.2.Specificconsiderations(27)
10.3.Wheredemonstrationofconformitybasedonclinicaldataisnotdeemedappropriate(29)
11.Theclinicalevaluationreport(CER,Stage4)(29)
12.Theroleofthenotifiedbodyintheassessmentofclinicalevaluationreports(31)
Appendices(32)
__.71revision4June2022年GuidelinesonMedicalDevicesClinicalEvaluation:
AGuideforManufacturersAndNotifiedBodiesUnderDirectives9342EECand__EEC
A1.Demonstrationofequivalence(32)
A2.Whenshouldadditionalclinicalinvestigationsbecarriedout?
(34)
A3.Devicedescription-typicalcontents(35)
A4.Sourcesofliterature(36)
A5.Literaturesearchandliteraturereviewprotocol,keyelements(37)
A5.1.Backgroundtotheliteraturesearchandtheliteraturereview(38)
A5.2.Objective(38)
A5.3.Methods(39)
A6.Appraisalofclinicaldata-examplesofstudiesthatlackscientificvalidityfordemonstrationofadequateclinicalperformanceand/orclinicalsafety(39)
A7.Analysisoftheclinicaldata-compliancetospecificEssentialRequirements(41)
A7.1.Conformityassessmentwithrequirementonsafety(MDDER1/AIMDDER1)(41)
A7.2.Conformityassessmentwithrequirementonacceptablebenefit/riskprofile
(MDDER1/AIMDDER1)(42)
A7.3.Conformityassessmentwithrequirementonperformance(MDDER3/AIMDDER2)(46)
A7.4.Conformityassessmentwithrequirementonacceptabilityofundesirableside-effects(MDDER6/AIMDDER5)(47)
A8.Devicesforunmetmedicalneeds-aspectstoconsider(48)
A9.Clinicalevaluationreport-proposedtableofcontents,examplesofcontents(49)
A10.Proposedchecklistforthereleaseoftheclinicalevaluationreport(54)
A11.Informationondeclarationsofinterests(56)
A12.Activitiesofnotifiedbodies(56)
A12.1.Notifiedbodyassessmentofclinicalevaluationbyconformityassessmentroute(56)
A12.2.Examinationofadesigndossier(AnnexII.4;Annex2.4)orofatypeexaminationdossier(AnnexIII;Annex3)(57)
A12.3.Evaluationaspartofqualitysystemrelatedprocedures(61)
A12.4.Notifiedbodyspecificproceduresandexpertise(62)
__.71revision4June2022年GuidelinesonMedicalDevicesClinicalEvaluation:
AGuideforManufacturersAndNotifiedBodiesUnderDirectives9342EECand__EEC
1.Introduction介绍
Pursuantto依据
-section6aofAnnexItoDirective93/42/EEC(amendedbyDirective2022年/47/EC)andto
-section5aofAnnex1toDirective90/385/EEC(amendedbyDirective2022年/47/EC),
thedemonstrationofconformitywithEssentialRequirementsforamedicaldevicemustincludeaclinicalevaluation,whichisconductedinaccordancewithAnnexXtoDirective93/42/EECorwithAnnex7toDirective90/385/EEC.
MDD指令93/42/EEC(amendedbyDirective2022年/47/EC)附录I的6a部分和
MDD指令90/385/EEC(amendedbyDirective2022年/47/EC)附录I的5a部分
和医疗器械的基本要求一致性的证明必须包含临床评价,根据Directive93/42/EEC的附录10和Directive90/385/EEC的附录7来指导。
Thisdocumentpromotesacommonapproachtoclinicalevaluationformedicaldevicesregulatedbydirectives90/385/EECand93/42/EEC.Itdoesnotconcerninvitrodiagnosticdevices.
Thedepthandextentofclinicalevaluationsshouldbeflexibleandappropriatetothenature,intendedpurpose,andrisksofthedeviceinquestion.Therefore,thisguidanceisnotintendedtoimposedevice-specificrequirements.
这个文件提供了按directives90/385/EECand93/42/EEC规定开展医疗器械临床评价的一般途径,不包含体外诊断试剂。
Thisdocumentusestheterms“must","shall","haveto"wherethesetermsareusedintheDirectives."Should"isusedinotherinstances.
本文档使用了术语“必须”、“应当”、“必须”这些术语使用的指令。
“应该”在其他情况下使用。
2.Scope范围
Thisguideisnotlegallybinding;onlythetextoftheDirectivesisauthenticinlaw.Itisrecognisedthatundergivencircumstances,forexampleasaresultofscientificdevelopments,analternativeapproachmaybepossibleorappropriatetocomplywiththe
legalrequirements.
本指南不具有法律约束力,只有在指令的文本是法律约束的。
在给定的情况下是被承认
的,例如作为科学发展的结果,另一种方法可能或适当的符合法律要求。
Nevertheless,duetotheparticipationofinterestedpartiesandofexpertsfromnationalCompetentAuthorities,itisanticipatedthatthisguidewillbefollowedwithintheMemberStates,therebysupportinguniformapplicationofrelevantprovisionsofEUDirectivesandcommonpractices.
__.71revision4June2022年GuidelinesonMedicalDevicesClinicalEvaluation:
AGuideforManufacturersAndNotifiedBodiesUnderDirectives9342EECand__EEC
然而,由于有利害关系人和国家主管部门的专家参与,预计本指南将在成员国跟从,从而支持欧盟相关指令的统一应用和一般做法。
OncertainissuesnotaddressedintheDirectives,nationallegislationmaybedifferentfromthisguide.
在指令中,某些问题不能被解决,国家法规可能不同于本指南。
Thisguideisregularlyupdatedaccordingtoregulatorydevelopments.Thelatestversionoftheguideshouldalwaysbeused.Thisversionisacompleterevisionoftheprevioustexts.ThemedicaldevicelegislationinEuropeiscurrentlybeingsignificantlyrevised.AnewRegulationoftheEuropeanParliamentandoftheCouncilonmedicaldeviceswillbepublished,whichmayresultinchangestoimportantconceptsordefinitionsrelatingtoclinicalevaluation.Partsorallofthisdocumentarelikelytoberevised.Somecontents(suchascontentsaboutnotifiedbodies)arelikelytoberemovedandintegratedinotherseriesofdocuments.
本指南将根据监管发展而定期更新,指南的最新版本总是被使用。
本版本完全修订了之前的文本。
欧洲的医疗器械法规目前正在大幅修订。
一项新规定的欧洲议会和理事会的医疗设备将发布,这可能导致临床评估相关的重要概念或定义发生变化。
部分或全部本文档可能会修订。
某些内容(如关于NB的内容)可能会被删除和综合其他系列文档中。
3.References